Immunotherapy markers
AssigneesVito NV, Universiteit Antwerpen
InventorsEline Berghmans, Geert Baggerman, Evelien Smits, Patrick Pauwels
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification and use of markers indicative for the response of a subject to immunotherapy as anti-cancer treatment. The markers are particularly useful in predicting response of a subject to immunotherapy with PD-1 or PD-L1 antagonists in the treatment of cancer. PD-1 and PD-L1 antagonists are typically used as immunotherapy in the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), and squamous cell carcinoma.
Claims12
A method of treating a subject with non-small cell lung cancer, the method comprising:
- determining whether a cancer sample from the subject comprises one or more antimicrobial peptides selected from the group consisting of neutrophil defensin 1, neutrophil defensin 2 and neutrophil defensin 3;
- and
- administering to the subject an effective amount of a PD-1/PD-L1 antagonist when one or more of the antimicrobial peptides are present within the cancer sample.
A method of diagnosing and treating a subject with a non-small cell lung cancer likely to respond to an immunotherapy, the method comprising:
- obtaining a cancer sample from the subject;
- detecting whether one or more antimicrobial peptides selected from the group consisting of neutrophil defensin 1, neutrophil defensin 2, and neutrophil defensin 3 is present in the sample by immunohistochemistry or MALDI-MSI;
- diagnosing the subject with a cancer likely to respond to the immunotherapy comprising a PD-1/PD-L1 antagonist when the presence of one or more antimicrobial peptides is detected;
- and
- administering an effective amount of the immunotherapy comprising the PD-1/PD-L1 antagonist to the diagnosed subject.
Dependencies are inferred from the claim text.